<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652051</url>
  </required_header>
  <id_info>
    <org_study_id>AZ201801</org_study_id>
    <nct_id>NCT03652051</nct_id>
  </id_info>
  <brief_title>A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)</brief_title>
  <official_title>A Multicenter, Vehicle-controlled, Randomized Study to Evaluate the Safety, Tolerability, Systemic Pharmacokinetics, and Pharmacodynamics of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD) and Evaporative Dry Eye Disease (DED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azura Ophthalmics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syneos Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azura Ophthalmics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AZ201801 is a multicenter study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients
      with Meibomian Gland Dysfunction (MGD) and evaporative Dry Eye Disease (DED)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AZ201801 is a multicenter, double-masked, vehicle-controlled, randomized, parallel group
      study carried out in 2 sequentially overlapping cohorts evaluating the safety, efficacy and
      tolerability of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland
      Dysfunction (MGD) and evaporative Dry Eye Disease (DED)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Meibum Gland Secretion Score (MGS)</measure>
    <time_frame>Month 3</time_frame>
    <description>Change from Baseline in MGS. The MGS can range from 0 (highly abnormal) to 45 (Normal)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Meibomian Glands Yielding Liquid Secretion (MGYLS)</measure>
    <time_frame>Month 3</time_frame>
    <description>Change from Baseline in MGYLS. The MGYLS can range from 0 (abnormal) to 15 (normal)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Meibum Gland Secretion Score (MGS)</measure>
    <time_frame>Day 14, Month 1, Month 1.5</time_frame>
    <description>Change from Baseline in MGS. The MGS can range from 0 (highly abnormal) to 45 (Normal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meibomian Glands Yielding Liquid Secretion (MGYLS)</measure>
    <time_frame>Day 14, Month 1, Month 1.5</time_frame>
    <description>Change from Baseline in MGYLS. The MGYLS can range from 0 (abnormal) to 15 (normal)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>AZR-MD-001 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZR-MD-001 Low Dose will be dosed up to once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZR-MD-001 Mid Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZR-MD-001 Mid Dose will be dosed up to once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZR-MD-001 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZR-MD-001 High Dose will be dosed up to once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZR-MD-001 Vehicle</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>AZR-MD-001 Vehicle will be dosed up to once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZR-MD-001 Low Dose</intervention_name>
    <description>AZR-MD-001 is an ophthalmic ointment</description>
    <arm_group_label>AZR-MD-001 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZR-MD-001 Mid Dose</intervention_name>
    <description>AZR-MD-001 is an ophthalmic ointment</description>
    <arm_group_label>AZR-MD-001 Mid Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZR-MD-001 High Dose</intervention_name>
    <description>AZR-MD-001 is an ophthalmic ointment</description>
    <arm_group_label>AZR-MD-001 High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZR-MD-001 Vehicle</intervention_name>
    <description>AZR-MD-001 is a vehicle ophthalmic ointment</description>
    <arm_group_label>AZR-MD-001 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 years of age or older

          -  Best-corrected visual acuity (BCVA) of 20/40 or better (Snellen equivalent), using the
             logarithm of the minimum angle of resolution (LogMAR) in each eye

          -  Evidence of meibomian gland obstruction

          -  Reported dry eye signs and symptoms within the past 3 months

        Exclusion Criteria:

          -  Uncontrolled ocular disease (except for MGD and dry eye disease/keratoconjunctivitis
             sicca) or uncontrolled systemic disease

          -  Glaucoma, ocular hypertension, or intraocular pressure (IOP) in either eye at
             screening â‰¥24 mm Hg or has planned insertion/removal of glaucoma filtration
             shunts/devices during the study

          -  Corneal abnormality or disorder that impacts normal spreading of the tear film or
             corneal integrity

          -  BCVA worse than 20/40 in either eye

          -  Current use of punctal plugs, anticipated insertion during the study, or a history of
             punctal cautery in either eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie L Watson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Save Sight Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Bosworth, PhD</last_name>
    <phone>714-559-8435</phone>
    <email>charles.bosworth@azuraophthalmics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Gleeson</last_name>
    <phone>+61 422 956 128</phone>
    <email>admin@azuraophthalmics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eye Associates</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Cohn, MD</last_name>
      <phone>+61 414 371 423</phone>
      <email>cohnclave@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sydney Eye Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie L Watson, MD</last_name>
      <phone>+61 (2) 9389 0666</phone>
      <email>stephanie.watson@sydney.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>School of Optometry and Vision Science, University of New South Wales</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Tan-Showlin, PhD, BOptom</last_name>
      <phone>+61 (02) 9385 6551</phone>
      <email>jacqueline.tan@unsw.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

